Periostin pp 195-204 | Cite as

Practical Application of Periostin as a Biomarker for Pathological Conditions

  • Isao KiiEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1132)


In physiological condition, periostin is expressed in limited tissues such as periodontal ligament, periosteum, and heart valves. Periostin protein is mainly localized on extracellular collagen bundles and in matricellular space. On the other hand, in pathological condition, expression of periostin is induced in disordered tissues of human patients. In tumor development and progression, periostin is elevated mainly in its microenvironment and stromal tissue rich in extracellular matrix. Tumor stromal fibroblasts highly express periostin and organize the tumor-surrounding extracellular matrix architecture. In fibrosis in lung, liver, and kidney, proliferating activated fibroblasts express periostin and replace normal functional tissues with dense connective tissues. In inflammation and allergy, inflammatory cytokines such as IL-4 and IL-13 induce expression of periostin that plays important roles in pathogenesis of these diseases. The elevated levels of periostin in human patients could be detected not only in tissue biopsy samples but also in peripheral bloods using specific antibodies against periostin, because periostin secreted from the disordered tissues is transported into blood vessels and circulates in the cardiovascular system. In this chapter, I introduce the elevated expression of periostin in pathological conditions, and discuss how periostin could be utilized as a biomarker in disease diagnosis.


Periostin Tumor Fibrosis Inflammation Allergy Antibody Diagnosis ELISA PET SPECT 


  1. 1.
    Ageyama N et al (2018) Successful inflammation imaging of non-human primate hearts using an antibody specific for tenascin-C. Int Heart J. CrossRefGoogle Scholar
  2. 2.
    Akabani G et al (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46:1042–1051PubMedGoogle Scholar
  3. 3.
    Akabani G et al (1999) Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors. J Nucl Med 40:631–638PubMedGoogle Scholar
  4. 4.
    Aloj L et al (2014) Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 41:867–877. CrossRefPubMedGoogle Scholar
  5. 5.
    Asakura M, Kitakaze M (2009) Global gene expression profiling in the failing myocardium. Circ J 73:1568–1576CrossRefGoogle Scholar
  6. 6.
    Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ (2009) Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol 34:821–828PubMedGoogle Scholar
  7. 7.
    Bozyk PD et al (2012) Neonatal periostin knockout mice are protected from hyperoxia-induced alveolar simplication. PLoS One 7:e31336. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chen X, Song E (2018) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. CrossRefGoogle Scholar
  9. 9.
    Contie S, Voorzanger-Rousselot N, Litvin J, Bonnet N, Ferrari S, Clezardin P, Garnero P (2010) Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. Calcif Tissue Int 87:341–350. CrossRefPubMedGoogle Scholar
  10. 10.
    Conway SJ et al (2014) The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 71:1279–1288. CrossRefGoogle Scholar
  11. 11.
    Desogere P, Montesi SB, Caravan P (2018) Molecular probes for imaging fibrosis and fibrogenesis. Chemistry. CrossRefGoogle Scholar
  12. 12.
    Dong XQ et al (2017) Serum periostin concentrations and outcomes after severe traumatic brain injury. Clin Chim Acta 471:298–303. CrossRefPubMedGoogle Scholar
  13. 13.
    Emson C, Pham TH, Manetz S, Newbold P (2018) Periostin and dipeptidyl peptidase-4: potential biomarkers of interleukin 13 pathway activation in asthma and allergy. Immunol Allergy Clin N Am 38:611–628. CrossRefGoogle Scholar
  14. 14.
    Francois H, Chatziantoniou C (2018) Renal fibrosis: recent translational aspects. Matrix Biol 68–69:318–332. CrossRefPubMedGoogle Scholar
  15. 15.
    Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M (2008) Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol 21:1044–1053. CrossRefPubMedGoogle Scholar
  16. 16.
    Garnero P (2014) New developments in biological markers of bone metabolism in osteoporosis. Bone 66:46–55. CrossRefPubMedGoogle Scholar
  17. 17.
    Gonzalez-Gonzalez L, Alonso J (2018) Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol 8:225. CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hakuno D et al (2010) Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents. J Clin Invest 120:2292–2306. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Heidari P, Esfahani SA, Turker NS, Wong G, Wang TC, Rustgi AK, Mahmood U (2015) Imaging of secreted extracellular periostin, an important marker of invasion in the tumor microenvironment in esophageal cancer. J Nucl Med 56:1246–1251. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Horiuchi K et al (1999) Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 14:1239–1249. CrossRefGoogle Scholar
  21. 21.
    Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957–2962. CrossRefPubMedGoogle Scholar
  22. 22.
    Ishikawa K et al (2014) Periostin promotes the generation of fibrous membranes in proliferative vitreoretinopathy. FASEB J 28:131–142. CrossRefPubMedGoogle Scholar
  23. 23.
    Izuhara K, Nunomura S, Nanri Y, Ogawa M, Ono J, Mitamura Y, Yoshihara T (2017) Periostin in inflammation and allergy. Cell Mol Life Sci 74:4293–4303. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Izuhara K, Ohta S, Ono J (2016) Using periostin as a biomarker in the treatment of asthma. Allergy Asthma Immunol Res 8:491–498. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jabbarli R et al (2018) Laboratory biomarkers of delayed cerebral ischemia after subarachnoid hemorrhage: a systematic review. Neurosurg Rev.
  26. 26.
    Jacobson O et al (2015) PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. J Nucl Med 56:616–621. CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Jia G et al (2012) Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 130:647–654. CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kashima TG et al (2009) Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum Pathol 40:226–237. CrossRefGoogle Scholar
  29. 29.
    Kashyap MK et al (2010) Overexpression of periostin and lumican in esophageal squamous cell carcinoma. Cancer 2:133–142. CrossRefGoogle Scholar
  30. 30.
    Kii I, Amizuka N, Minqi L, Kitajima S, Saga Y, Kudo A (2006) Periostin is an extracellular matrix protein required for eruption of incisors in mice. Biochem Biophys Res Commun 342:766–772. CrossRefGoogle Scholar
  31. 31.
    Kii I, Ito H (2017) Periostin and its interacting proteins in the construction of extracellular architectures. Cell Mol Life Sci 74:4269–4277. CrossRefPubMedGoogle Scholar
  32. 32.
    Kikuchi Y et al (2008) Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem 56:753–764. CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kikuchi Y et al (2014) The niche component periostin is produced by cancer-associated fibroblasts, supporting growth of gastric cancer through ERK activation. Am J Pathol 184:859–870. CrossRefPubMedGoogle Scholar
  34. 34.
    Kobayashi N et al (2011) Toward in vivo imaging of heart disease using a radiolabeled single-chain Fv fragment targeting tenascin-C. Anal Chem 83:9123–9130. CrossRefPubMedGoogle Scholar
  35. 35.
    Kondoh H, Nishiyama T, Kikuchi Y, Fukayama M, Saito M, Kii I, Kudo A (2016) Periostin deficiency causes severe and lethal lung injury in mice with bleomycin administration. J Histochem Cytochem 64:441–453. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kudo A, Kii I (2018) Periostin function in communication with extracellular matrices. J Cell Commun Signal 12:301–308. CrossRefGoogle Scholar
  37. 37.
    Kurihara H et al (2015) (64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients. EJNMMI Res 5:8. CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kurihara H et al (2016) Molecular imaging using PET for breast cancer. Breast Cancer 23:24–32. CrossRefPubMedGoogle Scholar
  39. 39.
    Kyutoku M et al (2011) Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int J Mol Med 28:181–186. CrossRefPubMedGoogle Scholar
  40. 40.
    Lee YJ et al (2013) Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol Ther 21:1004–1013. CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Liang C et al (2017) Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Exp Mol Med 49:e406. CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Liang C et al (2018) Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Cell Mol Life Sci 75:1001–1012. CrossRefPubMedGoogle Scholar
  43. 43.
    Liu AY, Zheng H, Ouyang G (2014) Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 37:150–156. CrossRefPubMedGoogle Scholar
  44. 44.
    Ma SM et al (2015) Periostin promotes neural stem cell proliferation and differentiation following hypoxic-ischemic injury. PLoS One 10:e0123585. CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Man F, Lammers T, de Rosales TM (2018) Imaging nanomedicine-based drug delivery: a review of clinical studies. Mol Imaging Biol 20:683–695. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Massicano AVF, Marquez-Nostra BV, Lapi SE (2018) Targeting HER2 in nuclear medicine for imaging and therapy. Mol Imaging 17:1536012117745386. CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Matsumoto H (2014) Serum periostin: a novel biomarker for asthma management. Allergol Int 63:153–160. CrossRefPubMedGoogle Scholar
  48. 48.
    Nagasaki T, Matsumoto H, Izuhara K, Ki HACRMG (2017) Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma. Allergol Int 66:404–410. CrossRefPubMedGoogle Scholar
  49. 49.
    Naik PK et al (2012) Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Phys Lung Cell Mol Phys 303:L1046–L1056. CrossRefGoogle Scholar
  50. 50.
    Nakama T et al (2016) Different roles played by periostin splice variants in retinal neovascularization. Exp Eye Res 153:133–140. CrossRefGoogle Scholar
  51. 51.
    Nakazawa T et al (2004) Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res 22:520–525. CrossRefGoogle Scholar
  52. 52.
    Nakazawa Y et al (2018) Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep 8:4013. CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Nam BY et al (2017) Periostin-binding DNA aptamer treatment ameliorates peritoneal dialysis-induced peritoneal fibrosis. Mol Ther Nucleic Acids 7:396–407. CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Nishiyama T et al (2011) Delayed re-epithelialization in periostin-deficient mice during cutaneous wound healing. PLoS One 6:e18410. CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Nitsche U et al (2016) Periostin and tumor-stroma interactions in non-small cell lung cancer. Oncol Lett 12:3804–3810. CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Norris RA et al (2007) Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J Cell Biochem 101:695–711. CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Norris RA, Moreno-Rodriguez R, Hoffman S, Markwald RR (2009a) The many facets of the matricelluar protein periostin during cardiac development, remodeling, and pathophysiology. J Cell Commun Signal 3:275–286. CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Norris RA et al (2009b) Periostin promotes a fibroblastic lineage pathway in atrioventricular valve progenitor cells. Dev Dyn 238:1052–1063. CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    O’Connor JP et al (2017) Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol 14:169–186. CrossRefPubMedGoogle Scholar
  60. 60.
    O’Dwyer DN, Moore BB (2017) The role of periostin in lung fibrosis and airway remodeling. Cell Mol Life Sci 74:4305–4314. CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Oka T et al (2007) Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res 101:313–321. CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Okamoto M et al (2011) Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 37:1119–1127. CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Ontsuka K et al (2012) Periostin, a matricellular protein, accelerates cutaneous wound repair by activating dermal fibroblasts. Exp Dermatol 21:331–336. CrossRefGoogle Scholar
  64. 64.
    Orecchia P et al (2011) Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer 47:2221–2229. CrossRefPubMedGoogle Scholar
  65. 65.
    Oskarsson T, Massague J (2012) Extracellular matrix players in metastatic niches. EMBO J 31:254–256. CrossRefPubMedGoogle Scholar
  66. 66.
    Paganelli G et al (1994) Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin. Eur J Nucl Med 21:314–321CrossRefGoogle Scholar
  67. 67.
    Popperl G, Gotz C, Gildehaus FJ, Yousry TA, Reulen HJ, Hahn K, Tatsch K (2002) Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV). Nuklearmedizin 41:120–128CrossRefGoogle Scholar
  68. 68.
    Qin X et al (2016) TGFbeta3-mediated induction of Periostin facilitates head and neck cancer growth and is associated with metastasis. Sci Rep 6:20587. CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Que-Gewirth NS, Sullenger BA (2007) Gene therapy progress and prospects: RNA aptamers. Gene Ther 14:283–291. CrossRefPubMedGoogle Scholar
  70. 70.
    Ratajczak-Wielgomas K, Dziegiel P (2015) The role of periostin in neoplastic processes. Folia Histochem Cytobiol 53:120–132. CrossRefPubMedGoogle Scholar
  71. 71.
    Rios H et al (2005) periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25:11131–11144. CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Roosenburg S et al (2014) PET and SPECT imaging of a radiolabeled minigastrin analogue conjugated with DOTA, NOTA, and NODAGA and labeled with (64)Cu, (68)Ga, and (111)In. Mol Pharm 11:3930–3937. CrossRefPubMedGoogle Scholar
  73. 73.
    Ruan K, Bao S, Ouyang G (2009) The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci 66:2219–2230. CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Sasada S et al (2017) Visualization of HER2-specific breast cancer intratumoral heterogeneity using (64)Cu-DOTA-trastuzumab PET. Eur J Nucl Med Mol Imaging 44:2146–2147. CrossRefPubMedGoogle Scholar
  75. 75.
    Sato M et al (2002) Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation 106:1397–1402CrossRefGoogle Scholar
  76. 76.
    Schold SC Jr et al (1993) Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Investig Radiol 28:488–496CrossRefGoogle Scholar
  77. 77.
    Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 9:135–187PubMedGoogle Scholar
  78. 78.
    Shimamura M et al (2012) Role of central nervous system periostin in cerebral ischemia. Stroke 43:1108–1114. CrossRefPubMedGoogle Scholar
  79. 79.
    Shimamura M et al (2014) Long-term expression of periostin during the chronic stage of ischemic stroke in mice. Hypertens Res 37:494–499. CrossRefPubMedGoogle Scholar
  80. 80.
    Shimazaki M et al (2008) Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 205:295–303. CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Sirica AE, Almenara JA, Li C (2014) Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. Exp Mol Pathol 97:515–524. CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Streit S, Michalski CW, Erkan M, Friess H, Kleeff J (2009) Confirmation of DNA microarray-derived differentially expressed genes in pancreatic cancer using quantitative RT-PCR. Pancreatology 9:577–582. CrossRefPubMedGoogle Scholar
  83. 83.
    Sung PL et al (2016) Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Oncotarget 7:4036–4047. CrossRefPubMedGoogle Scholar
  84. 84.
    Suzuki H et al (2004) Immunohistochemical localization of periostin in tooth and its surrounding tissues in mouse mandibles during development. Anat Rec A Discov Mol Cell Evol Biol 281:1264–1275. CrossRefGoogle Scholar
  85. 85.
    Suzuki H, Nishikawa H, Kawakita F (2018) Matricellular proteins as possible biomarkers for early brain injury after aneurysmal subarachnoid hemorrhage. Neural Regen Res 13:1175–1178. CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Takayama G et al (2006) Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 118:98–104. CrossRefGoogle Scholar
  87. 87.
    Tamura K et al (2013) 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 54:1869–1875. CrossRefPubMedGoogle Scholar
  88. 88.
    Taniyama Y et al (2016) Selective blockade of periostin exon 17 preserves cardiac performance in acute myocardial infarction. Hypertension 67:356–361. CrossRefGoogle Scholar
  89. 89.
    Tian Y et al (2015) Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLoS One 10:e0121502. CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Tsunoda T et al (2009) The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate 69:1398–1403. CrossRefPubMedGoogle Scholar
  91. 91.
    Tuwahatu CA, Yeung CC, Lam YW, Roy VAL (2018) The molecularly imprinted polymer essentials: curation of anticancer, ophthalmic, and projected gene therapy drug delivery systems. J Control Release 287:24–34. CrossRefPubMedGoogle Scholar
  92. 92.
    Uchida M et al (2012) Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. Am J Respir Cell Mol Biol 46:677–686. CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Um JE et al (2017) Periostin-binding DNA aptamer treatment attenuates renal fibrosis under diabetic conditions. Sci Rep 7:8490. CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Underwood TJ et al (2015) Cancer-associated fibroblasts predict poor outcome and promote periostin-dependent invasion in oesophageal adenocarcinoma. J Pathol 235:466–477. CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Venning FA, Wullkopf L, Erler JT (2015) Targeting ECM disrupts cancer progression. Front Oncol 5:224. CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Wang Z, Ouyang G (2012) Periostin: a bridge between cancer stem cells and their metastatic niche. Cell Stem Cell 10:111–112. CrossRefPubMedGoogle Scholar
  97. 97.
    Yamaguchi Y et al (2013) Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol 168:717–725. CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Zhou HM, Wang J, Elliott C, Wen W, Hamilton DW, Conway SJ (2010) Spatiotemporal expression of periostin during skin development and incisional wound healing: lessons for human fibrotic scar formation. J Cell Commun Signal 4:99–107. CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Zhu M, Saxton RE, Ramos L, Chang DD, Karlan BY, Gasson JC, Slamon DJ (2011) Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. Mol Cancer Ther 10:1500–1508. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Laboratory for Pathophysiological and Heath ScienceRIKEN Center for Biosystems Dynamics ResearchChuo-ku, KobeJapan
  2. 2.Compass to Healthy Life Research Complex ProgramRIKEN Cluster for Science, Technology and Innovation HubChuo-ku, KobeJapan

Personalised recommendations